Herbosa: Pharma Companies Vow Not to Increase Medicine Prices Until June | INQToday
Why It Matters
The price freeze shields Filipino patients from immediate cost spikes, yet the anticipated June hike underscores the urgency for local drug manufacturing and stronger regulatory oversight.
Key Takeaways
- •Pharma firms pledge no price hikes until June 2024.
- •Health Secretary Herbosa will monitor ten essential medicines.
- •Post‑June price rise expected due to rising shipping costs.
- •2008 Cheaper Medicines Act mandates price oversight by DTI, DILG.
- •Local production urged to create jobs and reduce import reliance.
Summary
The Department of Health announced that pharmaceutical companies have agreed not to raise retail prices on a core basket of medicines until June 2024, a decision made amid heightened geopolitical tensions in the Middle East that could disrupt supply chains. Health Secretary Theodoro Herbosa said the pledge emerged from a recent meeting with industry leaders and will be enforced under the 2008 Cheaper Medicines Act, which tasks the DTI and DILG with monitoring drug costs.
Herbosa will closely track ten high‑use medicines—covering hypertension, diabetes, cholesterol, antibiotics and others—to prevent price gouging. He warned that once the current three‑month inventory buffer expires in June, companies may need to adjust prices upward to offset rising shipping expenses and other input costs.
The secretary also urged manufacturers to shift production to the Philippines, citing potential job creation and reduced reliance on imports. He highlighted that local manufacturing could stabilize supply, lower logistics costs, and support the broader goal of health‑sector self‑sufficiency.
For consumers, the temporary freeze offers short‑term relief, but the looming post‑June increase could strain household budgets. Policymakers will need to balance price stability with incentives for domestic production, while regulators remain vigilant to ensure compliance with the act’s price‑monitoring provisions.
Comments
Want to join the conversation?
Loading comments...